Aberrant activation and upregulation of the Wnt pathway is a key feature of many cancers. Wnt antagonists have recently attracted wide attention. Wnt inhibitory factor-1 (WIF-1) is a secreted antagonist that can bind to Wnt proteins directly and inhibit Wnt signaling pathway. It has been reported that WIF-1 expression is down regulated in several solid tumors and that WIF-1 is silenced by promoter hypermethylation in lung and colorectal cancer. By using RT-PCR, bisulfite sequence analysis, and methylation-specific PCR, we analysed expression and methylation of WIF-1 in cancer cell lines and freshly resected cancer tissues of the esophagus, stomach, colorectum, and pancreas. Downregulation of WIF-1 mRNA expression was observed in 61 (91.0%) of 67 cancer cell lines, 16 (80.0%) of 20 esophageal, 23 (74.2%) of 31 gastric, 41 (82.0%) of 50 colorectal, and six (75.0%) of eight pancreatic cancer tissues. Downregulation of WIF-1 expression was also observed at protein level. No significant association between WIF-1 downregulation and clinicopathological characteristics was found, suggesting that downregulation of WIF-1 expression is an early event in carcinogenesis of these cancers. Indeed, downregulation of WIF-1 expression was observed in 32 (72.7%) of 44 colorectal adenoma tissues and 18 (78.2%) of 23 early mucosal or submucosal colorectal carcinoma tissues. CpG island hypermethylation in the WIF-1 promoter region correlated with downregulation of WIF-1 expression in cancer cell lines and tissues. Treatment with demethylating agent, 5-aza-2 0 -deoxycytidine (5-aza-dC), restored WIF-1 expression in cancer cell lines. A combined treatment of 5-aza-dC and a histone deacetylase inhibitor, trichostatinA, restored WIF-1 expression synergistically, indicating the role of cytosine methylation and histone deacetylation in the silencing of the WIF-1 gene. Transfection of the WIF-1 gene construct into TE-1 esophageal cancer cell lines or SW48 colon cancer cell lines lacking WIF-1 expression resulted in a significant inhibition on colony formation, cell proliferation, anchorageindependent growth in soft agar. TOPflash assay showed WIF-1 inhibits Wnt canonical signaling in these cell lines.
Aberrant activation and upregulation of the Wnt pathway is a key feature of many cancers. Wnt antagonists have recently attracted wide attention. Wnt inhibitory factor-1 (WIF-1) is a secreted antagonist that can bind to Wnt proteins directly and inhibit Wnt signaling pathway. It has been reported that WIF-1 expression is down regulated in several solid tumors and that WIF-1 is silenced by promoter hypermethylation in lung and colorectal cancer. By using RT-PCR, bisulfite sequence analysis, and methylation-specific PCR, we analysed expression and methylation of WIF-1 in cancer cell lines and freshly resected cancer tissues of the esophagus, stomach, colorectum, and pancreas. Downregulation of WIF-1 mRNA expression was observed in 61 (91.0%) of 67 cancer cell lines, 16 (80.0%) of 20 esophageal, 23 (74.2%) of 31 gastric, 41 (82.0%) of 50 colorectal, and six (75.0%) of eight pancreatic cancer tissues. Downregulation of WIF-1 expression was also observed at protein level. No significant association between WIF-1 downregulation and clinicopathological characteristics was found, suggesting that downregulation of WIF-1 expression is an early event in carcinogenesis of these cancers. Indeed, downregulation of WIF-1 expression was observed in 32 (72.7%) of 44 colorectal adenoma tissues and 18 (78.2%) of 23 early mucosal or submucosal colorectal carcinoma tissues. CpG island hypermethylation in the WIF-1 promoter region correlated with downregulation of WIF-1 expression in cancer cell lines and tissues. Treatment with demethylating agent, 5-aza-2 0 -deoxycytidine (5-aza-dC), restored WIF-1 expression in cancer cell lines. A combined treatment of 5-aza-dC and a histone deacetylase inhibitor, trichostatinA, restored WIF-1 expression synergistically, indicating the role of cytosine methylation and histone deacetylation in the silencing of the WIF-1 gene. Transfection of the WIF-1 gene construct into TE-1 esophageal cancer cell lines or SW48 colon cancer cell lines lacking WIF-1 expression resulted in a significant inhibition on colony formation, cell proliferation, anchorageindependent growth in soft agar. TOPflash assay showed WIF-1 inhibits Wnt canonical signaling in these cell lines.
These results suggest tumor suppressive function of WIF-1, due to its ability to inhibit Wnt signaling. Our results suggest that WIF-1 silencing due to promoter hypermethylation is an important mechanism underlying aberrant activation of the Wnt signaling pathway in carcinogenesis of the digestive organs. Modulation of the Wnt pathway, through reversal of WIF-1 silencing by demethylating agents, is a potential target for treatment and/or prevention of gastrointestinal cancers. Aberrant activation and upregulation of the Wnt pathway is a key feature of many cancers (Kolligs et al., 2002; Giles et al., 2003; Lustig and Behrens, 2003) . Inactivating mutations in APC, Axin, Axin-2, and b-TrCP genes or activating mutations in the b-catenin gene have been identified in up to 70% of benign and malignant tumors (Lustig and Behrens, 2003) . Overexpression of Wnt genes has been reported in many cancers (Kolligs et al., 2002; Giles et al., 2003; Lustig and Behrens, 2003) . Moreover, Wnt antagonists have recently been identified and their role in carcinogenesis is becoming characterized (Hsieh et al., 1999; Suzuki et al., 2002 Suzuki et al., , 2004 Kawano and Kypta, 2003; Caldwell et al., 2004) .
Wnt antagonists can be divided into two broad classes. These molecules prevent ligand-receptor interactions (Kawano and Kypta, 2003) . The first class, including the secreted frizzled-related protein (sFRP) family, Wnt inhibitory factor-1 (WIF-1), and Cerberus, inhibits Wnt signaling by direct binding to Wnt proteins. The second class comprises certain members of the Dickkopf (Dkk) family, which bind to the LRP5/LRP6 component of the Wnt receptor complex (Kawano and Kypta, 2003) .
WIF-1 was first identified as an expressed sequence tag from the human retina (Hsieh et al., 1999) . WIF-1 is expressed during development in paraxial presomitic mesoderm, notochord, branchial arches, and neural crest derivatives. Although WIF-1 does not share any similarities with the cysteine-rich domain of frizzled (Fz) or sFRPs, WIF-1 binds to Drosophila Wingless and Xenopus Wnt-8 in the extracellular space and inhibit Wnt-8-Fz2 interactions (Hsieh et al., 1999; Kawano and Kypta, 2003) . WIF-1 has an NH 2 -terminal signal sequence, a unique WIF domain (WD) that is highly conserved across species, and five epidermal growth factor (EGF)-like repeats (Hsieh et al., 1999; Kawano and Kypta, 2003) .
Downregulation of WIF-1 protein expression has been reported in human prostate, bladder, breast, and nonsmall-cell lung carcinomas (Wissmann et al., 2003) . Recently, Mazieres et al. (2004) reported that WIF-1 was silenced by promoter hypermethylation in lung cancer cell lines and tissues. More recently, He et al. (2005) have shown that WIF-1 is silenced by promoter hypermethylation in colorectal cancer. Previous studies have shown aberrant activation and upregulation of the Wnt pathway in the majority of colorectal cancers and less frequently in other gastrointestinal cancers such as gastric cancer (Ikenoue et al., 2002; Kolligs et al., 2002; Mizushima et al., 2002; Giles et al., 2003; Lustig and Behrens, 2003) . Moreover, epigenetic inactivation of sFRPs has been reported in early colorectal carcinogenesis (Suzuki et al., 2004) . These findings make WIF-1 relevant to investigations of gastrointestinal cancers. Thus, we analysed the expression and epigenetic regulation of WIF-1 in cancers of the esophagus, stomach, colorectum, and pancreas.
Silencing of WIF-1 by promoter hypermethylation in human cancer cell lines: We examined WIF-1 mRNA expression in cancer cell lines by using semiquantitative RT-PCR (Figure 1a ). The WIF-1 mRNA expression was lost or considerably reduced in 14 (73.7%) of 19 esophageal, 11 (84.6%) of 13 gastric, 17 (73.9%) of 23 colorectal, six (100%) of six hepatocellar, four (80.0%) of five pancreatic, and five (71.4%) of seven endometrial cancer cell lines. Methylation status of the CpG islands was analysed in esophageal cancer cell lines. The bisulfite sequencing method was used to analyse methylation status of 60 CpG sites in the 672-bp fragment of WIF-1 including the promoter from À554 to þ 118 in TE-1, TE-5, and TE-8 esophageal cancer cell lines (Figure 1b and data not shown). These CpG islands were densely methylated in TE-1 cells lacking WIF-1 mRNA expression but not in TE-5 or TE-8 cells expressing WIF-1. Methylation status of WIF-1 was further analysed in TE cell lines by using methylationspecific PCR (MSP) (Figure 1c ). Only unmethylated bands were detected in WIF-1-expressing cell lines, TE-4, TE-5, and TE-8 cells. Both unmethylated and methylated bands were detected in TE-3, TE-9, and TE-10 cells expressing low levels of WIF-1. Only methylated bands were detected in other TE cell lines lacking WIF-1 mRNA expression. Silencing of WIF-1 mRNA expression was correlated with hypermethylation of its promoter in gastrointestinal cancer cell lines ( Figure 1d ). To further examine the role of methylation and histone deacetylation in silencing of WIF-1, TE-1, DLD-1, SW48, and SW480 cells were treated with 5-aza-2 0 -deoxycytidine (5-aza-dC) and/or trichostatinA (TSA) (Figure 1e and data not shown). 5-aza-dC restored WIF-1 expression, and combined treatment of 5-aza-dC and TSA restored WIF-1 expression synergistically. Treatment with TSA alone had no effect on gene expression.
Silencing of WIF-1 by promoter hypermethylation in gastrointestinal cancer tissues: WIF-1 expression and methylation status were analysed in gastrointestinal cancer tissue samples. Downregulation of WIF-1 mRNA expression was observed in 16 (80.0%) of 20 esophageal, 23 (74.2%) of 31 gastric, 41 (82.0%) of 50 colorectal, and six (75.0%) of eight pancreatic cancer tissues compared with expression in their matched normal tissue samples (Figure 2 ). No significant association between WIF-1 mRNA downregulation and clinicopathological characteristics was found (data not shown). Aberrant methylation was observed in all tumor samples with down-regulated WIF-1 mRNA expression ( Figure 3 and data not shown). WIF-1 protein expression was detected in normal tissues. WIF-1 protein expression was either low or hardly detectable in tumor tissues with methylation, while the expression was retained in tumor tissues without methylation ( Figure 3 and data not shown). Thus, the methylation status of WIF-1 was correlated with mRNA and protein expression in all cases (Po0.001). Slight methylated bands were observed in several normal tissues adjacent to the tumor, suggesting premalignant changes of peritumoral normal tissue. Unmethylated bands detected in tumor tissues suggest monoallelic methylation and/or contamination of nontumor cells in tumor specimens. Expression and methylation status of WIF-1 were further analysed in 44 colorectal adenoma tissues and 23 early carcinoma tissues with mucosal or submucosal invasion. Downregulation of WIF-1 mRNA expression was observed in 32 (72.7%) of 44 adenoma tissues and 18 (78.2%) of 23 early carcinoma tissues. Aberrant methylation was observed in all tumor samples with WIF-1 down-expression and the methylation status was correlated with WIF-1 mRNA expression (Po0.001; data not shown).
Tumor suppression effects of WIF-1: Tumor suppression effects of WIF-1 were analysed by colony formation assay, cell proliferation assay, and soft agar assay. In colony formation assay, TE-1 cells were transfected with WIF-1 expression vector or empty vector. After selection of G418-resistant colonies for 3 weeks, the colony numbers of WIF-1-transfected cells were significantly lower than those of empty vector-transfected cells (Po0.01) (Figure 4a ). Following G418 selection, 10 clones were randomly chosen from each transfection and subjected to semiquantitative RT-PCR and immunoblot analysis to determine the level of WIF-1 expression in these clones. Four WIF-1-transfectants with different levels of WIF-1 expression, TE-1 WIF 1 (low), TE-1 WIF 4 (low), TE-1 WIF 5 (high), and TE-1 WIF 8 (high), were selected for further analysis (Figure 4b ). The levels of WIF-1 expression in WIF-1-transfectants were within the range when esophageal cancer cell lines endogenously expressed WIF-1 (data not shown). TOPflash assay showed significant reduction in TCF-dependent transcriptional activity in TE-1 clones stably expressing WIF-1 (Po0.01; Figure 4c ). TE-1 cells and transfectants were then examined for their growth rates on the culture plates. The growth rates of TE-1 clones stably expressing WIF-1 were significantly lower than those of empty vector-transfected TE-1 clones (Po0.01; Figure 4d) . Moreover, the (NUGC3, NUGC4, SNU1, SNU638, MKN1,  MKN28, MKN45, MKN74 , KATOIII, GT3TKB, HGC27, GC1Y, and AZ521), duodenal adenocarcinoma cell line (TGBC18TKB), colorectal adenocarcinoma cell lines (DLD1, HCT8, HCT15, HCT116, LoVo, LS123, LS174T, LS180, SW48, BM314, CaCO2, CaR1, CoCM1, Colo320DM, Colo320HSR, HT29, RCM1, SKCO1, SW480, SW620, SW1116, SW1417, and WiDr), hepatocellular carcinoma cell lines (Hep3B, HepG2, HLE, HLF, HuH7, and PLC/PRF/5), biliary tract adenocarcinoma cell lines (TGBC1TKB, TGBC2TKB, and HuCCT), pancreatic cancer cell lines (BxPC3, Kp4, MiAPaCa, Panc1, and SuSu86), endometrial cancer cell lines (AN3CA, HEC1A, HEC1B, HHUA, SKUT1, SKUT1B, SKOV3), prostatic cancer cell line (DU145), ovarian cancer cell line (Cal51), and breast cancer cell line (MCF7) were purchased from the Japanese Cancer Research Resources Bank (Tokyo, Japan), Riken Cell Bank (Tokyo), or the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in DMEM or RPMI1640 supplemented with 10% fetal bovine serum. Total RNA from cell lines and tissue samples were extracted using an extraction kit (RNeasy Mini kit; Qiagen, Valencia, CA, USA). cDNA was synthesized from 2 mg of total RNA using SuperScript III reverse transcriptase (Invitrogen, San Diego, CA, USA) with random hexamers. PCR was performed using primers specific for the WIF-1 gene and the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes. GAPDH served as an internal control of the reaction. All reactions were controlled without reverse transcriptase. Results were analysed using a multi-image analyser (Bio-Rad, Richmond, CA, USA). The levels of gene transcripts were quantified as the ratio of the intensity of the WIF-1 gene to the intensity of GAPDH. To perform semiquantitative RT-PCR, the ranges of linear amplification for the WIF-1 gene and for the GAPDH gene were studied by using standard curves. Standard curves were drawn by using logarithmically serially diluted plasmids containing amplified region of each target gene. The correlation between the quantity of cDNA before PCR and the band intensities of target genes was analysed using a hemi-logarithmic scale. The linear relationships were determined by the least-squares approximation. Thus, the optimal number of PCR cycles and the optimal mixing ratio of primers were determined. After confirming the specificity of each primer set, we used those primers published previously . (b) Representative results of bisulfite sequence analysis of WIF-1 in esophageal cancer cell lines. Bisulfite modification of genomic DNA and bisulfite sequencing were performed as described previously (Herman et al., 1996; Mazieres et al., 2004) . Two pairs of primers, 5 0 -GAGTGATGTTTTAGGGGTTT-3 0 and 5 0 -CCTAAATAC CAAAAAACCTAC-3 0 , designed to amplify nucleotides À555 to þ 140 of the WIF-1 promoter region, and 5 0 -GTAGGTTTTTTGG TATTTAGG-3 0 and 5 0 -TCCATAAATACAAACTCTCCTC-3 0 , to amplify nucleotides À161 to þ 118 of the WIF-1 gene, were used . Unmethylated CpG sites are indicated by open circles and methylated CpG sites are indicated by filled circles. The arrows represent primers for MSP. (c) RT-PCR and MSP analysis of WIF-1 in esophageal cancer cell lines. MSP analysis of WIF-1 promoter was performed as described previously using primers corresponding to the WIF-1 promoter region sequences À488 to À468 and À310 to À290 . (d) MSP analysis of WIF-1 in cancer cell lines. (e) Reactivation of WIF-1 expression by 5-aza-dC treatment in a colon cancer cell line SW48. Cells were treated with 1 mM of 5-aza-dC (Sigma, St Louis, MO, USA) for 72 h or with 300 nM of TSA for 24 h. Cells were also treated with 1 mM of 5-aza-dC for 72 h followed by 300 nM of TSA for an additional 24 h. The timing and sequencing of 5-aza-dC and/or TSA was based on similar preliminary studies as well as published studies (Cameron et al., 1999) . Immediately after completion of treatments, cells were harvested for RNA purification. RT-PCR was performed after 5-aza-dC and/or TSA treatment. At the top of the lane, '5-aza-dC' indicates treatment with 1 mM of 5-aza-dC for 72 h and 'TSA' indicates treatment with 300 nM of TSA for 24 h. '5-aza-dC þ TSA' indicates treatment with 1 mM of 5-aza-dC for 72 h followed by treatment with 300 nM of TSA for 24 h Epigenetic loss of WIF-1 in gastrointestinal cancers H Taniguchi et al growth rates of TE-1 clones stably expressing high levels of WIF-1 were significantly lower than those of TE-1 clones stably expressing low levels of WIF-1 (Po0.01; Figure 4d ). To determine the effect of WIF-1 expression on anchorage-independent growth of TE-1 cells, we performed colony formation assay in soft agar of TE-1 cells and transfectants. The numbers of colonies formed by TE-1 clones stably expressing WIF-1 were significantly lower than those of empty vector-transfected TE-1 clones (Po0.01; Figure 4e and f). Moreover, the numbers of colonies formed by TE-1 clones stably expressing high-levels of WIF-1 were significantly lower than those of TE-1 clones stably expressing low levels of WIF-1 (Po0.01; Figure 4e and f). Similar tumor suppression effects of WIF-1 were observed in SW48 colon cancer cell clones stably expressing WIF-1 (data not shown).
In discussion we demonstrated downregulation of WIF-1 expression in 73.7% of esophageal, 84.6% of gastric, 73.9% of colorectal, 100% of hepatocellar, 80.0% of pancreatic, and 57.1% of endometrial cancer cell lines at mRNA level. As a mechanism of WIF-1 downregulation in cancer, Mazieres et al. (2004) and He et al. (2005) recently reported that WIF-1 was silenced by promoter hypermethylation in lung and colorectal cancer. By using bisulfite sequence analysis and MSP, we demonstrated that silencing of WIF-1 was also correlated with hypermethylation of its promoter in various gastrointestinal cancer cell lines. To confirm the role of DNA methylation in transcriptional repression of the WIF-1 gene, we treated several gastrointestinal cancer cell lines, in which WIF-1 was methylated, with 5-aza-dC alone or in combination with TSA. Treatment with 5-aza-dC restored the WIF-1 expression in the cancer cell lines. Moreover, combined treatment of 5-aza-dC and TSA restored WIF-1 expression synergistically, indicating the cytosine methylation and histone deacetylation play a role in silencing the WIF-1 gene.
The results of in vitro studies were supported by results for primary cancer tissues. WIF-1 mRNA expression was down-regulated in 80.0% of esophageal, 74.2% of gastric, 82.0% of colorectal, and 75% of pancreatic cancer tissues compared with expression in their matched normal tissues. Downregulation of WIF-1 expression was also observed at protein level. No significant association was found between WIF-1 downregulation and clinicopathological characteristics, suggesting that downregulation of WIF-1 expression is an Figure 2 RT-PCR analysis of WIF-1 in primary esophageal (a), gastric (b), and colorectal (c) cancer tissues. Paired specimens of tumor and adjacent nontumor tissues of the esophagus, stomach, colorectum, and pancreas were obtained from patients who had undergone surgical or endoscopic treatment. Each tumor tissue specimen was divided into three pieces after resection. For total RNA and DNA extraction, two samples were immediately frozen in liquid nitrogen at the time of surgery or polypectomy and stored at À801C until extraction. The remaining sample was processed for pathological examination using hematoxylin and eosin staining for the evaluation of the tumor cell content. Only specimens containing more than 80% tumor cells were used for analysis. Histopathological features of the specimens were classified according to the pathological tumor-node-metastasis (TNM) classification system of the Union International Contre Cancer. Informed consent was obtained from each subject and the institutional review committee approved the experiments. Downregulation of WIF-1 was judged when WIF-1 gene expression in the tumor sample was at least four times lower than that in the corresponding normal sample. N and T, matched samples from non-tumor and tumor tissue, respectively Figure 3 (a) RT-PCR, immunoblot, and MSP analysis of primary esophageal, gastric, and colorectal cancer tissues. For immunoblot analysis, frozen tissues or cell lines were homogenized in lysis buffer (50 mM Tris-HCl (pH 7.4), 1% Triton X-100, 1 mM diethyldithiocarbamic acid, 1 mM EDTA, 1% Tween 20, 10 mM leupeptin, and 1 mM phenylmethylsulfonyl fluoride) on ice. After sonication and centrifugation (10 000 g at 41C), protein content of the supernatant was measured by the method of Bradford. Solubilized proteins (100 mg) were separated by SDS-PAGE and transferred to a polyvinylidene difluoride transfer membrane. After being blocked with 5% blocking agent, the membrane was incubated with an antihuman WIF-1 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and developed using the enhanced chemiluminescene system (Amersham, Arlington Heights, IL, USA). The membrane was then stripped and reincubated with a polyclonal anti-actin antibody (Sigma, St Louis, MO, USA). Results were analysed using a multi-image analyser (Bio-Rad, Richmond, CA, USA). The levels of protein expression were quantified as the ratio of the intensity of WIF-1 expression to that of actin expression. Downregulation of WIF-1 expression was judged when WIF-1 expression in the tumor sample was at least four times lower than that in the corresponding normal sample. Assays to determine colony formation in soft agar by cancer cell lines were performed using 60 mm tissue culture dishes containing a bottom layer consisting of 4 ml culture medium containing 0.5% (w/v) agarplaque (BD PharMingen, San Diego, CA, USA) and a top layer of 0.25% (w/v). Aliquots of parental cells, empty vector-transfected clones, and clones stably expressing WIF-1 were plated at a density of 5000 cells/plate between the two layers of agar, and experiments were performed in triplicate. Visible colonies were counted after 3 weeks of incubation by taking micrographs from 16 randomly selected fields. (f) Average numbers of colonies of TE-1 cells and transfectants. The assay was performed in triplicate and colonies were counted from multiple randomly selected fields. Data collected from each experimental group were expressed as mean7s.d. and paired t test was used for statistical analysis. *Po0.01 and **Po0.01 early event in gastrointestinal carcinogenesis. Moreover, WIF-1 mRNA expression was down-regulated in 72.7% of colorectal adenomas and 78.2% of early colorectal carcinomas with mucosal or submucosal invasion. These results further support the notion that WIF-1 silencing is an early event in colorectal carcinogenesis. By using MSP, we demonstrated that silencing of WIF-1 was correlated with hypermethylation of its promoter in primary gastrointestinal cancer tissue samples. These results suggest that epigenetic silencing of WIF-1 is one of the most important mechanisms of aberrant activation of the Wnt signaling pathway in gastrointestinal carcinogenesis.
Additionally, we investigated whether restoration of WIF-1 would result in tumor suppression in cancer cell lines in which WIF-1 is silenced. Transfection of the WIF-1 gene construct into TE-1 or SW48 cell lines lacking WIF-1 expression resulted in a significant inhibition on colony formation, cell proliferation, and anchorage-independent growth in soft agar. We have demonstrated the correlation between WIF-1 expression levels and the degree of tumorigenicity inhibition. Moreover, TOPflash assay showed significant reduction in TCF-dependent transcriptional activity in clones stably expressing WIF-1. Thus, WIF-1, due to its ability to inhibit Wnt signaling, may have tumor suppressive function. Loss or downregulation of the antagonist function of WIF-1 may hypersensitize the tumor to Wnt.
There are 19 human Wnt genes so far. These ligands have various functions in Wnt signaling pathway. It has been reported that Wnt-1, but not Wnt-5A and Wnt-7A, induces b-catenin/TCF-dependent transcription in esophageal cancer cells (Mizushima et al., 2002) . Wnt-14 has been frequently detected in esophageal and pancreatic cancer (Kirikoshi et al., 2001) . Frequent upregulation of Wnt-2 and Wnt-5A has been reported in gastric and colorectal cancer (Smith et al., 1999; Katoh, 2001; Holcombe et al., 2002; Saitoh et al., 2002) . He et al. (2005) reported that Wnt-1 is overexpressed and plays an important role in colorectal cancer. Thus, different gastrointestinal cancers appear to have different members of predominant Wnt ligands. Therefore, it is interesting to know whether WIF-1 is a universal antagonist to all Wnt ligands or just to specific Wnt ligands in different gastrointestinal cancers (He et al., 2005) . Although b-catenin is constitutively active in the majority of colorectal tumors and less frequently in other gastrointestinal cancers, it is possible that WIF-1 can act in the canonical Wnt pathway (He et al., 2005) . It is also possible that the reduced activity or absence of WIF-1 allows the transduction of noncanonical Wnt signals, which contribute to tumor progression.
It has been thought that WIF-1 can be a downstream target gene of the Wnt/b-catenin pathway and may function as a feedback inhibitor of Wnt signaling, although the Wnt/b-catenin pathway may not be the only pathway that controls WIF-1 expression (Cebrat et al., 2004; Reguart et al., 2004) . In this regard, epigenetic downregulation of WIF-1 function may provide constitutive Wnt signaling that is required to complement downstream mutations in the development and progression of cancer.
Hypermethylation of the WIF-1 gene may provide a useful marker for detecting preinvasive and early-stage cancer amenable to cure and/or for predicting the risk of cancer. Modulation of the Wnt pathway, through reversal of WIF-1 silencing by demethylating agents, is a potential target for treatment and/or prevention of gastrointestinal cancers.
